



## Insights Into Breast Cancer

September 16, 2020

Presenter: William Gradishar, MD, FACP

Moderator: Keren Sturtz, MD

### AGENDA

Time (CT)	Topic
5.30 PM – 5.45 PM (15 min)	<b>Introduction</b> <ul style="list-style-type: none"> <li>• Program overview</li> <li>• Baseline ARS questions</li> </ul>
5.45 PM – 6.45 PM (30 min presentation; 30 min discussion)	<b>Treatment of HR-Positive Advanced Breast Cancer</b> <ul style="list-style-type: none"> <li>• Overview of current data <ul style="list-style-type: none"> <li>– Initial endocrine therapy: Single agent vs combination with CDK4/6 inhibitor <ul style="list-style-type: none"> <li>▪ Impact of prior adjuvant therapy, disease-free interval, disease and patient characteristics</li> <li>▪ Specific considerations for premenopausal patients</li> </ul> </li> <li>– Targeted therapy for <i>PIK3CA</i>-mutated disease</li> <li>– Treatment of progressive disease: Choice of next-line endocrine therapy, impact of prior treatment, monotherapy vs combinations with targeted agents (eg, everolimus, CDK4/6 inhibitor [beyond progression?])</li> <li>– When to switch to chemotherapy, choice of initial and later-line treatment</li> </ul> </li> <li>• Reaction and discussion</li> </ul>
6.45 PM – 7.30 PM (20 min presentation; 25 min discussion)	<b>Treatment of HER2-Positive Advanced Breast Cancer</b> <ul style="list-style-type: none"> <li>• ARS questions</li> <li>• Overview of current data <ul style="list-style-type: none"> <li>– Initial therapy: Is dual HER2 blockade the standard? <ul style="list-style-type: none"> <li>▪ Which HER2-targeted agents? Would you use a biosimilar?</li> <li>▪ Which chemotherapy partner?</li> <li>▪ Impact of prior adjuvant therapy, disease-free interval, disease and patient characteristics</li> </ul> </li> <li>– Treatment of progressive disease: TDM-1 vs other options</li> <li>– Next-generation anti-HER2 agents</li> </ul> </li> <li>• Reaction and discussion</li> </ul>
7.30 PM – 7.40 PM (10 min)	<b>BREAK</b>
7.40 PM – 8.20 PM (20 min presentation; 20 min discussion)	<b>Treatment of Triple-Negative Advanced Breast Cancer</b> <ul style="list-style-type: none"> <li>• ARS questions</li> <li>• Overview of current data <ul style="list-style-type: none"> <li>– Initial chemotherapy – preferred regimen, role of platinum compounds in practice, taxane selection (eg, nab-paclitaxel)</li> <li>– Later lines of chemotherapy – role of eribulin and other agents, impact of prior therapy</li> </ul> </li> </ul>

	<ul style="list-style-type: none"> <li>- Role of PARP inhibitors – approach to germline and somatic <i>BRCA</i> mutation testing, current views on “<i>BRCAness</i>” and homologous recombination deficiency as biomarkers</li> <li>- Immunotherapy (± nab-paclitaxel)</li> <li>- Promising investigational targets and immunotherapy</li> </ul> <ul style="list-style-type: none"> <li>• Reaction and discussion</li> </ul>
8.20 PM – 8.30 PM (10 min)	<b>Key Takeaways and Meeting Evaluation</b>